BioCentury | Jan 2, 2012
Company News

Acumen Pharmaceuticals, Merck deal

Acumen said Merck terminated an amended 2003 deal and returned rights to develop and commercialize anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease. According to Acumen, Merck made the decision based on...
BioCentury | Dec 22, 2011
Company News

Merck ends AD deal with Acumen

Acumen Pharmaceuticals Inc. (Livermore, Calif.) said Merck & Co. Inc. (NYSE:MRK) terminated a 2003 deal and returned rights to develop and commercialize anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease. According to...
BioCentury | Sep 12, 2011
Politics, Policy & Law

Biodefense report card

Ten years after 9/11 and the subsequent anthrax attacks alerted America to the threat posed by bioterrorism, progress in developing and procuring vaccines and drugs to protect the civilian population has been frustratingly slow. An...
BioCentury | Oct 29, 2007
Regulation

Late-stage NI studies

Late-stage NI studies Company Product Indication [status] Trial(s) Trial design ICH E10 Advanced Life Sci/ Abbott Cethromycin Community-acquired pneumonia requiring hospitalization (hCAP) [Ph III] Ph III CL-05 & CL-06 trials 1º endpoint: clinical cure rate...
BioCentury | Jan 29, 2007
Company News

Acumen Pharmaceuticals, Merck deal

...disease (AD) (see BioCentury, Dec. 4, 2006). The payment was triggered by undisclosed development activities. ADDLs...
BioCentury | Dec 4, 2006
Company News

Acumen Pharmaceuticals, Merck deal

...2004 agreement, giving MRK exclusive R&D rights to diagnostic products directed at amyloid-derived diffusible ligands (ADDLs...
...AD), as well as an option to develop a vaccine (see BioCentury, Jan. 19, 2004). ADDLs...
BioCentury | May 15, 2006
Strategy

Merck protein therapeutics deals

Merck protein therapeutics deals Company Year Description Abmaxis 2006 Acquires Abmaxis for $80M in cash. The Abmaxis in-silico Immunization (AISIM) technology uses a structure-based approach to designing MAbs tailored for a specific therapeutic application. Abmaxis...
BioCentury | May 30, 2005
Finance

VPOs into the breach

Biotech startups have been complaining that the venture community is less willing to fund very early stage technologies than in the past. As a result, there is a gap between academic discoveries and the translational...
BioCentury | Jul 12, 2004
Strategy

Merck's small company epiphany

Not so long ago, Merck & Co. Inc. was pharma's poster child for not-invented-here syndrome. But of late, the company has been engaged in one of the more aggressive bouts of preclinical and discovery stage...
BioCentury | Mar 15, 2004
Strategy

Fitting in with Merck

Fitting in with Merck Compound Status Target/MOA Alzheimer's disease c-9136 Ph II NA c-7617 Ph I NA c-9138 Ph I NA Acumen deal Preclin/ disc Vaccines, antibodies targeting amyloid-derived diffusible ligand (ADDL) Sunesis deal Preclin/...
Items per page:
1 - 10 of 14